Sotatercept denied due to quantity / dose limits by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for sotatercept are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Applies Quantity Limits to Sotatercept

UHC may apply quantity limits to sotatercept — restricting coverage to a defined amount per dispensing period — as a utilization management tool. Quantity limits for sotatercept typically reflect an attempt to align coverage with a standard dosing interval as described in the FDA-approved prescribing information. A quantity-limit denial most commonly occurs when the prescribed quantity does not match UHC's default limit, even when the prescription is clinically appropriate.

Important: The correct dose and dosing interval for your patient are determined by the FDA-approved prescribing label and the prescribing specialist — not by the insurer's quantity limit. When those differ, the quantity limit can be challenged.

## Common Reasons for Quantity-Limit Denials

• Prescription quantity written for a quantity or frequency that differs from the plan's programmed limit.
• Dosing based on patient-specific clinical factors (body weight, clinical response) that result in a quantity outside the default.
• Administrative mismatch between drug strength and the units entered by the pharmacy.

## Your Appeal Rights

• Quantity-limit exception: Request a quantity exception directly from UHC. The prescribing specialist must explain in writing why the prescribed quantity is medically necessary and consistent with the FDA-approved label.
• Internal appeal (ERISA §503 / ACA §2719): File a formal internal appeal if the exception is denied. Submit the FDA label dosing information and the prescriber's clinical justification.
• External review: After exhausting internal remedies, request external review by an IRO — file within the window on your Explanation of Benefits, typically approximately four months. External reviewers apply the FDA label and clinical standards.
• Expedited review: If the quantity limit is causing a treatment gap for a PAH patient, request expedited review given the progressive nature of the disease.

## Documentation to Gather

1. FDA prescribing label: Obtain the current FDA-approved prescribing information for sotatercept from DailyMed or the manufacturer. Identify the dosing section and confirm that the prescribed quantity aligns with it. 2. Prescriber justification letter: A letter from the specialist explaining that the prescribed quantity matches the FDA-approved dosing protocol and, if patient-specific factors affect the quantity, documenting those factors from the chart. 3. Pharmacy documentation: Confirm the NDC, strength, and quantity as dispensed versus as prescribed — administrative mismatches are common and fixable. 4. Diagnosis and severity documentation: Chart notes confirming the PAH diagnosis and clinical status, supporting the need for ongoing therapy.

## Criteria-Mapping Structure

Obtain UHC's published quantity-limit table for sotatercept. Compare the plan's stated limit against the FDA label's dosing section line by line. Document the discrepancy explicitly in your appeal letter. If the FDA label supports the prescribed quantity, state that clearly and attach the relevant label pages.